⚠️ Serious warning: Nothing on this website is approved by any physician. Doz is only a tool to help physicians and to search drugs easily. Taking medicines without medical supervision can be fatal.

Naloxegol

نالوکسگول

⚠ Unverified

🍽️ Alimentary Tract And MetabolismPeripherally acting opioid antagonist (PAMORA)

🤰 Pregnancy:Use with caution 🤱 Breastfeeding:Dangerous / avoid 👶 Children:Use with caution 👴 Older adults:No specific problem stated 🇮🇷 Not found in Iran list ⛔ 1 contraindications 🇺🇸 FDA approved (NDA) NDA204760 ATC A06AH03

Market / country: 🇺🇸 USA

Movantik (US)

🧮 Dose calculator

Disease / regimen

Opioid-induced constipation · Regimen source: FDA Movantik · 2.2

• If not tolerated: 12.5 mg. Moderate CYP3A4 inhibitors: avoid or 12.5 mg. Stop maintenance laxatives. FDA Movantik · 2.2 FDA Movantik · 2.4 FDA Movantik · 2

Formulation

Age *

Weight (kg) (optional)

Enter age (weight is optional for this regimen).

🛡️ Safety & information

Contraindications

⛔ Known or suspected GI obstruction; strong CYP3A4 inhibitors (clarithromycin, ketoconazole); hypersensitivity. FDA Movantik · 4

Warnings

• GI perforation; severe diarrhoea or abdominal pain; opioid withdrawal. FDA Movantik · 5

Renal adjustment

• eGFR < 60: CrCl <60: start 12.5 mg. FDA Movantik · 2.3

Formulations

25 mg tablet — tablet 🇺🇸 USA FDA Movantik · 3
12.5 mg tablet — tablet 🇺🇸 USA FDA Movantik · 3

👥 Special populations

🤰 PregnancyUse with caution
Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Movantik · 8.1
“Risk Summary Limited available data with MOVANTIK use in pregnant women are insufficient to inform a drug associated risk of adverse developmental outcomes.”
🤱 BreastfeedingDangerous / avoid
Label: breastfeeding not recommended, or choose between the drug and breastfeeding. FDA Movantik · 8.2
“Because of the potential for adverse reactions, including opioid withdrawal in breastfed infants, advise women that breastfeeding is not recommended during treatment with MOVANTIK.”
👶 ChildrenUse with caution
The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Movantik · 8.4
“The safety and effectiveness of MOVANTIK have not been established in pediatric patients.”
👴 Older adultsNo specific problem stated
Label: no specific difference or dose adjustment stated for older adults. FDA Movantik · 8.5
“No dosage adjustment is needed in elderly patients.”
⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.

🔗 Reference links

FDA (approval record)NDA204760
DailyMed (FDA label)FDA Movantik
MedlinePlus (NIH)Naloxegol
WHO ATC/DDDA06AH03
Darooyab (Iran)❌ None

🇮🇷 Not found in Iran list Darooyab · search

Darooyab lists no registered dosage form or brand for this drug. This does not prove it is unavailable.

📚 Reference status for this drug

Shows which sources have references recorded for this drug and which do not.

FDA label (DailyMed)✅ Present
FDA Movantik · 3 FDA Movantik · 2.2 FDA Movantik · 2.4 FDA Movantik · 2 FDA Movantik · 4 FDA Movantik · 5 FDA Movantik · 2.3 FDA Movantik · SPL approval / marketing category FDA Movantik · 8.1 FDA Movantik · 8.2 FDA Movantik · 8.4 FDA Movantik · 8.5
UK SmPC (eMC / MHRA)❌ Not present
Published guideline❌ Not present
Licensed reference (medical school)❌ Not present
Iranian leaflet (IFDA)❌ Not present
Pharmacy website (secondary, unreliable)✅ Present
Darooyab · search
Clinical review⚠ Unverified